People · Operator
Named in public records as an officer, director or promoter · active 2015–2015 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alucent Biomedical, Inc. | — | Biotechnology | Series B | $46.6M | $134.2M | 2015 |
David Kapaska at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Kapaska on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Myles Greenberg | 1 | 6 |
| Daniel Pelak | 1 | 5 |
| Michael Elliot | 1 | 4 |
| Nick Pappas | 1 | 4 |
| Myles D. Greenberg | 1 | 3 |
| James Corbett | 1 | 3 |
| Kevin Warner | 1 | 1 |
| Colin Jackson | 1 | 1 |
| David Flicek | 1 | 1 |
| Katalin Kauser | 1 | 1 |
| James Isaacson | 1 | 1 |
| Henry Hauser | 1 | 1 |
| Dan D. Pelak | 1 | 1 |
| David N. Flicek | 1 | 1 |
| James D. Corbett | 1 | 1 |
| Scott N. Mayfield | 1 | 1 |
| Ryan D. Hansen | 1 | 1 |
| Pat D. Costello | 1 | 1 |
| Julie N. Lautt | 1 | 1 |
| Julie Norton | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.